Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543692 | 0.88 | L3MBTL1 (0.49) | L3MBTL1APPNPY1R | |
| SCHEMBL17138602 | 0.82 | ELANE (0.46) | L3MBTL1 | |
| SCHEMBL13824487 | 0.82 | SRC (0.48) | SRCGRM2L3MBTL1HRH3ENPP2 | |
| SCHEMBL5220521 | 0.81 | SRC (0.50) | SRCGRM2L3MBTL1HRH3ENPP2 | |
| Hydrochloric Acid SCHEMBL4491429 | 0.80 | SRC (0.49) | SRCGRM2L3MBTL1HRH3ENPP2 | |
| SCHEMBL7950295 | 0.76 | SRC (0.67) | SRCAPPNPY1R | |
| SCHEMBL12844868 | 0.75 | L3MBTL1 (0.54) | L3MBTL1APPNPY1R | |
| SCHEMBL20570052 | 0.73 | ENPP2 (0.50) | SRCGRM2L3MBTL1HRH3ENPP2 | |
| SCHEMBL24938208 | 0.73 | L3MBTL1 (0.84) | GRM2L3MBTL1HRH3ENPP2 | |
| SCHEMBL27109640 | 0.72 | SRC (0.64) | SRCAPPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550453-B2 | Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide | AVENTIS PHARMA SA (FR) | 2009-06-23 | — | — | US | disclosed |
| US-7550453-B2 | Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide | AVENTIS PHARMA SA (FR) | 2009-06-23 | — | — | US | disclosed |
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-10-18 | — | — | US | disclosed |
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | HCCS, ALKBH2, ALKBH3 | SRC 716/4885GRM2 3044/4885L3MBTL1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.